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[57] ABSTRACT 
A method of reducing corneal scarring or ?broblast prolif 
eration comprises applying to an area of a subject’s eye 
af?icted With the condition a corneal scar-?broblast 
proliferation-reducing amount of a free or polymer-bound 
HLE inhibitory agent under conditions and for a period of 
time effective to attain the desired effect. A method of 
reducing neovasculariZation of corneal scar tissue comprises 
applying to an area of a subject’s eye afflicted with the 
condition a neovasculariZation-inhibitory amount of a free 
or polymer-bound HLE inhibitory agent under conditions 
and for a period of time effective to attain the desired effect. 
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METHODS OF TREATING EYE 
CONDITIONS WITH HUMAN LEUKOCYTE 
ELASTASE (HLE) INHIBITORY AGENTS 
TECHNICAL FIELD 
This invention relates to methods of treating corneal 
scarring or ?broblast proliferation by applying to the ocular 
area a human leukocyte elastase (HLE) inhibitory agent in a 
prescribed amount. 
BACKGROUND OF THE INVENTION 
Proteinases from polymorphonuclear leukocytes and 
macrophages, especially elastases (human leukocyte 
elastase and cathepsin G), appear to be responsible for the 
chronic tissue destruction associated With in?ammation, 
arthritis and emphysema. During infection or in?ammation 
the normal lung is protected from proteolytic digestion by 
the protease inhibitor al-antitrypsin. The protective mecha 
nism appears to be non-operative in individuals With an 
al-antitrypsin de?ciency due to genetic or other causes. 
Synthetic elastase inhibitors capable of replacing 
al-antitrypsin therefore appear to be useful in the treatment 
of pulmonary emphysema and related diseases. 
Several types of elastase inhibitors have been reported in 
the literature. These include peptide chloromethyl ketones as 
described in “Inhibition of Human Leukocyte Elastase by 
Peptide Chloromethyl Ketones”, P. M. Tuhy and J. C. 
PoWers, FEBS Letters, 50, 359—61 (1975); “Speci?city of 
Porcine Pancreatic Elastase, Human Leukocyte Elastase and 
Cathepsin G. Inhibition With Peptide Chloromethyl 
Ketones”, J. C. PoWers, B. F. Gupton, A. D. Harley, N. 
Nishino and R. J. Whitley, Biochem. Biophys. Acta. 485, 
156—66 (1977); aZapeptides “Proteinase Inhibitors. 1. 
Inhibitors of Elastase”, C. P. Dorn, M. Zimmerman, S. S. 
Yang, E. C. YureWicZ, B. M. Ashe, R. Frankshun and H. 
Jones, J. Med. Chem., 20: 1464—68 (1977); “Reaction of 
Serine Proteases With AZa-amino Acid and AZa-peptide 
Derivatives”, J. C. PoWers and B. F. Gupton, Meth. 
EnZymol., 46: 208—16 (1977); sulfonyl ?uorides “Speci?c 
ity and Reactivity of Human Leukocyte Elastase, Porcine 
Pancreatic Elastase, Human Granulocyte Cathepsin G, and 
Bovine Pancreatic Elastase, Human Granulocyte Cathepsin 
G, and Bovine Pancreatic Chymotrypsin With Arylsulfonyl 
Fluorides”; “Discovery of a neW series of potent and speci?c 
irreversible Elastase Inhibitors”, T. Yoshimura, L. N. Barker 
and J. C. PoWers, J. Biol. Chem., 257, 5077—84 (1982-); 
heterocyclic acrylating agents “Inhibition of Elastase and 
Other Serine Proteases by Heterocyclic Acylating Agents”, 
M. Zimmerman, H. Morman, D. Mulvey, H. Jones, R. 
Frankshun and B. M. Ashe, J. Biol. Chem., 255: 9848—51 
(1980); “Selective Inhibition of Human Leukocyte Elastase 
and Bovine ai-Chymotrypsin by Novel Heterocycles”, B. M. 
Ashe, R. L. Clark, H. Jones and M. Zimmerman, J. Biol. 
Chem., 256: 11603—6 (1981); imidaZole N-carboxamides, 
W. C. Groutas, R. C. Badger, T. D. Ocain, D. Felker, J. 
Frankson and M. Theodorakis, Biochem. Biphys. Res. 
Commun., 95: 1890 (1980); and p-nitrophenyl-N alkyl 
carbamates, “p-Nitrophenyl Carbamates as Active-Site 
Speci?c Reagents for Serine Proteases”, R. E. Sco?eld, R. P. 
Werner and F. Wold, Biochemistry, 16: 2492 (1977). 
Although some peptide chloromethyl ketones have been 
shoWn to be effective in preventing elastase induced emphy 
sema in animal models there is considerable question 
Whether such reactive agents could be used for treating 
emphysema in humans. (“Prevention of Elastase Induced 
Experimental Emphysema by Oral Administration of a Syn 
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thetic Elastase Inhibitor,” A. Janoff and R. Dearing, Am. J. 
Respir. Dis., 121: 1025—3 (1980)). This is not surprising 
since the alkylating moieties in these inhibitors might render 
them toxic When used on a continuous basis. To be suitable 
for human use, an enZyme inhibitor has to shoW a high 
degree of selectively and must have minimal toxic side 
effects. As a result, most drugs are molecules that reversibly 
bind to speci?c enZymes or receptor sites. Examples are the 
carbamate esters physostigmine and neostigmine Which 
have been clinically used as inhibitors of acetyl choline 
esteraces, A. G. Gilman, L. S. Goodman and A. Gilman, 
“The pharmacological Basis of Therapeutics”, p. 101, Mac 
Millan Publishing Co. (1980). 
A series of peptide elastase inhibitors Were disclosed in 
US. Pat. No. 4,643,991 to Digenis et al. Another group of 
polymer-bound elastase inhibitors Was disclosed in US. 
application Ser. No. 242,294 by Digenis et al. ?led on Sep. 
9, 1988, now US. Pat. No. 5,162,307, issued Nov. 10, 1992. 
Still other peptidyl carbamate inhibitors of the enZyme 
elastase Were disclosed in US. application Ser. No. 07/263, 
385 entitled “Novel Peptidyl Carbamate Inhibitors of the 
EnZyme Elastase” by Digenis et al., ?led on Oct. 27, 1988, 
now US. Pat. No. 5,008,245, issued Apr. 16, 1991. The 
latter Digenis application also provides methods of inhibit 
ing the enZyme elastase With the peptidyl carbamate agents 
described therein. The contents of the Digenis et al patent 
and applications referenced above are incorporated herein 
by reference to the extent that they enable the speci?c HLE 
inhibitory agents described therein and their methods of 
preparation. 
Various conditions of the eye are knoWn to be associated 
With corneal scarring and ?broblast proliferation, amongst 
them ocular coagulation and burns, mechanical and chemi 
cal injury, ocular infections such as kerato-conjunctivitis, 
and other ocular conditions. Some of these conditions are 
knoWn to arise post-operatively after surgical treatment of 
other ocular conditions. This undesirable tissue groWth is 
easily neovasculariZed and therefore becomes permanently 
established and irrigated. Tissue scarring or ?broblast pro 
liferation is a condition Which is dif?cult to treat. Presently, 
it is treated by subjecting the ocular area to further surgery 
or by using steroids, topically or by injection. HoWever, 
steroids do increase side effects such as infection, cataract 
and glaucoma. Other non-steroidal agents like indomethcin 
have very little anti-scarring effects. (Williamson J. et al., 
British J. of Ophthalmology 53:361 (1969); Babel, J., His 
tologie Der Crtisonkatarakt, p.327. Bergmann, Munich 
(1973)). 
Even after further surgery the proliferation of ?broblastic 
tissue continues to occur and further scar tissue appears. 
Thus, in addition to surgery being an extremely invasive 
procedure, the results attained thereof are not entirely sat 
isfactory. 
Accordingly, there remains a need in the art for methods 
of reducing and/or preventing the formation of corneal scar 
tissue or ?broblast proliferation Which are not subject to the 
disadvantages of methods knoWn in the art for this purpose. 
SUMMARY OF THE INVENTION 
This invention relates to a method of reducing corneal 
scarring or ?broblast proliferation comprising applying to an 
area of a subject’s eye af?icted With the condition a corneal 
scar- or ?broblast proliferation-reducing amount of a human 
leukocyte elastase (HLE) inhibitory agent under conditions 
and for a period of time effective to attain the desired effect. 
Also part of this invention is a method of reducing 
neovasculariZation of corneal scar tissue comprising apply 
5,922,319 
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ing to an area of a subject’s eye af?icted With the condition 
a neovasculariZation-inhibitory amount of an HLE inhibi 
tory agent under conditions and for a period of time effective 
to attain the desired effect. 
A more complete appreciation of the invention and many 
of the attendant advantages thereof Will be readily perceived 
as the same becomes better understood by reference to the 
following detailed description When considered in connec 
tion With the accompanying ?gures. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a print of a histological microscopic photograph 
of a corneal tissue as described in Table 2. This photograph 
shoWs a pathology section of an untreated corneal burn. 
Excessive in?ammation and ?broblastic activity (thin 
arroWs) can be seen. Severe neovascular formation is 
marked With thick short arroWs (H&E Stain x200). 
FIG. 2 is a print of a histological microscopic photograph 
of a corneal tissue described in Table 2. This photograph 
shoWs a pathology section of a corneal burn treated With the 
inhibitor of this invention. As can be seen, the degree of 
in?ammation, scarring and neovascular formation is mini 
mal and has been greatly reduced When compared With FIG. 
1, the control eye (H&E Stain x200). 
FIGS. 3, 5 and 7 are pathology sections of rabbit corneas 
that Were thermally burned and treated for tWo Weeks With 
polyvinyl alcohol. Severe in?ammatory reaction is seen 
including formation of polymorphonuclear neutrophils, 
eosinophils, ?broblasts, and granulation tissue (arroWs) 
(HematoXylin and eosin x100). 
FIGS. 4, 6 and 8 shoW pathology sections of rabbit 
corneas that Were thermally burned and treated With the 
inhibitor of this invention for tWo Weeks. As can be seen, the 
in?ammatory reaction is much reduced in comparison to the 
control eyes (untreated) shoWn in FIGS. 3, 5 and 7. 
In?ammation, scarring and neovasculariZation are much 
reduced When compared With the control eyes (HematoXylin 
and eosin x100). 
Other objects, advantages and features of the present 
invention Will become apparent to those skilled in the art 
from the folloWing discussion. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
This invention arose from a desire to improve over prior 
art methods for treating ocular scarring or ?broblast 
proliferation, particularly When it occurs in the cornea of the 
eye. 
The inventors have found for the ?rst time that if an HLE 
inhibitory agent is applied to a subject’s eye it has an 
inhibitory effect on the proliferation and groWth of ?bro 
blasts or scar tissue. For the ?rst time the inventors have 
shoWn that HLE inhibitors have an ophthomological appli 
cation. 
Thus, the present invention relies on the therapeutic 
application of HLE inhibitory agents to the corneal area of 
the eye to prevent and/or reduce corneal scarring or ?bro 
blast proliferation as Well as neW vasculariZation. These 
conditions have been found to be associated With a variety 
of pathological states of the eye such as infections, burns and 
mechanical and chemical injury, among others. 
The inhibitory agents utiliZed in the present methods may 
be applied to the eye topically, intraocularly, by injection or 
through a contact lens. Preferred is topical. By means of 
eXample the agents may be applied as a solution in a solvent 
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Which is not detrimental to the functions of the eye. 
Typically, an aqueous solution of the HLE inhibitory agent 
may be utiliZed. HoWever, given that some HLE inhibitory 
agents are cleared very limpidly from the eye, they may also 
be bound to a Water soluble or hydrophilic polymer to ensure 
a more prolonged residence in the desired area. The aqueous 
solution may also contain other ingredients as is knoWn in 
the art. 
This invention thus provides a method of reducing corneal 
scarring or ?broblast proliferation Which comprises apply 
ing to an area of a subject’s eye af?icted With the condition 
a corneal scar- or ?broblast proliferation-reducing amount of 
an HLE inhibitory agent under conditions and for a period 
of time effective to attain the desired effect. 
Any HLE inhibitory agent may be utiliZed When practic 
ing the method of the invention. Typically, many HLE 
inhibitory agents are knoWn in the art as discussed above and 
need not be further described herein. By means of example, 
inhibitory agents Which are suitable for use With this inven 
tion are those described in US. Pat. No. 4,643,991 and US. 
Pat. No. 5,008,245 both to Digenis et al. Aseries of peptide 
elastase inhibitors Were disclosed in US. Pat. No. 4,643,991 
to Digenis et al. These peptide elastase inhibitors are car 
bamates substituted by oligopeptides and may generally be 
described by the folloWing general formula (I): 
(I) 
o 
R1 
Wherein Z is selected from the group consisting of R“O-Suc 
Where R“ is loWer alkyl of 1 to 3 carbon atoms and 
CF3CO—; X is oXygen or sulfur, R‘ is selected from the 
group consisting of straight or secondary branched-chain 
alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon atoms, 
alkynyl of 2 to 4 carbon atoms, cycloalkyl of 3 to 6 carbon 
atoms, preferably cyclopropyl or cycloheXyl, and benZyl, 
and R is selected from the group consisting of substituted or 
unsubstituted phenyl Wherein the substituents are selected 
from the group consisting of nitro, preferably p-nitro, and 
?uoro, preferably penta?uoro, benZyl, CH2CF2CF2CF3, 
1-loWer alkyl tetraZolyl-, 1-phenyltetraZolyl-, 2-thioXo-3 
thiaZolindyl, pyridyl, and benZothiaZolyl, provided that 
When R is paranitrophenyl, R‘ is other than tertiary-butyl, 
benZyl or cycloheXyl, and When X is sulfur, R is other than 
benZyl. 
In more preferred embodiments, the inhibitory peptides 
may be described by the folloWing general formulae Ia or Ib: 
(Ia) 
O 
Wherein X‘ is oXygen or sulfur and R2 is selected from the 
group consisting of phenyl, ?uorophenyl, nitrophenyl, 
1-phenyltetraZolyl, 1-loWer alkyl tetraZolyl, benZyl, 
3-thiaZolidinyl, pyridyl, and benZothiaZolyl, and R1 is 
straight or secondary branch chained alkyl of 2 to 4 carbons, 
alkenyl of 2 to 4 carbons, and alkynyl of 2 to 4 carbons, 
provided that When R2 is p-nitrophenyl, R1 is other than 
tertiary-butyl, and When X‘ is sulfur, R2 is other than benZyl; 
and 
5,922,319 
(1b) 
R3 
wherein Z‘ is selected from the group consisting of MeO 
Suc-Ala-Ala and CF3CO-Ala-Ala, Wherein R3 is as de?ned 
for R1 above, but is preferably isopropyl. 
However, other HLE inhibitory agents may also be uti 
liZed for practicing the present method. 
As already indicated above, the HLE inhibitory agents 
may be bound to a hydrophilic or Water-soluble polymer in 
order to eXtend their residence in the area to Which they are 
applied. The HLE inhibitory agents may be covalently 
bound to any hydrophilic and/or Water-soluble polymer 
Which does not detrimentally affect the function of the eye. 
Many such polymers are knoWn in the art and discussed in 
US. Pat. No. 5,162,307 to Digenis et al. The polymer-bound 
HLE inhibitory agent described in the referenced application 
are suitable for practicing this invention. An eXample of the 
group of polymer-bound elastase inhibitors useful in the 
present invention, as disclosed in US. Pat. No. 5,162,307 to 
Digenis et al., have the folloWing structures: 
A Polymer of the formula 
P—(L-R4)q (II) 
Wherein P is a polymer comprising at least one unit of the 
formula (AmBn) Wherein (AmBn) is substantially nonbiode 
gradable and has an average molecular Weight of about 
1,000 to 500,000 daltons, m and n may be the same or 
different and are about 5 to 3,000, and A and B may be the 
same or different and at least one of A and B is capable of 
covalently binding to one of L and R4; 
Wherein R4 is a compound selected from the group 
consisting of 
(i) a compound C of the formula 
wherein 
X1 is oxygen or sulfur; 
R5 is selected from the group consisting of straight and 
secondary branch-chained (C1—C4) alkyl, (C2—C3) alkenyl, 
(C2—C4) alkynyl, (C3—C6) cycloalkyl, and benZyl; and 
R6 is selected from the group consisting of substituted and 
unsubstituted phenyl, Wherein the substituents are selected 
from the group consisting of nitro, and penta?uoro, benZyl, 
CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl, 
1-phenyltetraZolyl, 2-thioXo-3-thiaZolidinyl, pyridyl and 
benZothiaZolyl, provided that When R6 is p-nitrophenyl R5 is 
other than tert-butyl, benZyl or cycloheXyl, and When X1 is 
sulfur R6 is other than benZyl: 
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(ii) a compound D of the formula: 
(D) 
O 
—O—Suc—Ala—Ala—Pro—CH2' N—("I—X2-R8 
IL? 
Wherein 
X2 is O or S. 
R8 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, CH2CF2CF2CF3, 1-loWer 
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3 
thiaXo-3-thiaZolidinyl, pyridyl and benZothiaZolyl, and 
R7 is selected from the group consisting of straight or 
secondary branch chained (C1—C4) alkyl, (C2—C3) alkenyl, 
(C2—C4) alkynyl, (C3—C6) cycloalkyl, and benZyl, provided 
that When R8 is p-nitrophenyl R7 is other than tertiary-butyl, 
benZyl or cycloheXyl, and When X2 is sulfur R8 is other than 
benZyl; and 
(iii) a compound E of the formula 
(E) 
Wherein 
Z2 is —O—Suc-Ala-Ala: 
each said R4 being covalently bound to L or to one of A 
and B, 
L is selected from the group consisting of a covalent bond 
and a linker group Which is covalently bound to R4 and one 
of A and B; and 
q is about 1 to m+n. 
More preferred compounds according to the Us. Pat. No. 
5,162,307 are compounds Wherein 
A is a compound of the formula 
(Ila) 
— HN — CH — (cH2)m2— co — 
(TI-12x12 
CO 
Wherein m2=0 or 1 and n2=1 or 0 respectively and R9 is 
selected from the group consisting of OH, 2-hydroXyethyl 
amine, 2-hdroXypropylamine, 3-hydroXypropyl amine, 2,3 
dihydroXypropyl amine, 2-hydroXybutylamine and 
4-hydroXybutylamine; and 
B is a compound of the formula (Ila) above, Wherein R9 
is selected from the group consisting of NH2, NH—NH2, 
NH—NH2, —NH—R1O—NH2 wherein R10 is (C2—C10) 
alkyl or (C6—C8) aryl, and NH—R11—OH Wherein R11 is 
(C2—C8) alkyl or (C6—C8) aryl. 
Particularly preferred are compounds Wherein the poly 
mer P is poly-(x1[3-(N(2-hydroXyethyl)-D,L-asparagine), a 
copolymer derived from poly(N-2-vinylpyrrolidone) or a 
5,922,319 
polysaccharide selected from the group consisting of X3R15 is 
deXtran, carboXyrnethyl cellulose, alginic acid and hydru 
ronic acid. 
Also preferred in Us. Pat. No. 5,162,307 are compounds 
Wherein 
A is selected from the group consisting of N-2 
vinylpyrrolidone, N-hydroXypropylrnethacrylarnide, 
2-hydroXyethyl rnethacrylate and acrylarnide, 
B is selected from the group consisting of amino (C2—C6) 
alkylrnethacrylarnide, arnino (C2—C6) alkylacrylarnide, 10 
amino (C2—C6) alkyl rnaleic acid rnonoarnide, O-alkyl acry 
(IV) 
A compound selected from the group consisting of a 
compound of the formula 
(III) 
X3Rl5 
P1 
l l l 
l l l 
l l l 
l l l 
l l l 
l l l 
l l l 
l l l 
l l l 
l l l 
o: O :Y : l l l 
\RLL : N I | N Tl l l l l l 
CH3 : : O: 
l l l 
l l l 
P3 I P2 I P1 I ' 
20 
l 
O l 
| 
l 
N | 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
l 
| 
P2 | 
| 
45 
| 
| 
| 
| 
| 
| 
| 
| 
: 
o I 
| 
MeO ' 
I N 
I | 
o I H 
: 
PS I 
late and rnethacrylate Where alkyl is of the general formula 
CH2—CH(OH)—CH2—NH—R12—NH2 Where R12 is 
C2—C6 hydrocarbon. 
Even more preferred in the Us. Pat. No. 5,162,307 are 15 
compounds Wherein 
A and B are one and the same. 
The most preferred and particular species of compounds 
as stated in the Us. Pat. No. 5,162,307 are incorporated 
herein by reference thereto. 
Still other peptide or peptidyl carbarnate inhibitors of the 
enzyme elastase Were disclosed in US. Pat. No. 5,008,245 
to D1gen1s et al , WhlCh are useful In the present invention 
and have the following structures 
l l 
l l 
O : CH3 : 
MeO : : 
l l 
l l 
O I O I 
l l 
l l 
l l 
l l 
l l 
l l 
l l 
l l 
l l 
l l 
P5 | P4 | 
l I 
wherein X is 1 or 2, 
Y is carbobenZoXy or benZoyl, and 
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(46a) p-Nitrophenyl N-[Methoxysuccinyl-(Né 
carbobenZoxy)-L-ornithyl-L-alanyl-L-prolylmethyl]-N 
isopropylcarbamate 
(46b) p-Nitrophenyl-(N6-carbobenZoxy)-L-ornithyl-L 
alanyl-D-prolylmethyl]-N-isopropylcarbamate, 
(47a) p-Nitrophenyl N-[Methoxysuccinyl-(N 6-benZoyl)-L 
ornithyl-L-alanyl-L-prolylmethyl]-N-isopropylcarbamate, 
(47b) p-Nitrophenyl N-[Methoxysuccinyl-(Né-benzoyl)-L 
ornithyl-L-alanyl-D-prolylmethyl]-N isopropylcarbamate, 
(48a) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€ 
carbobenZoxy)-L-prolylmethyl]-N-isopropylcarbamate, 
(48b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€ 
carbobenZoxy)-L-lysyl-D-prolylmethyl]-N 
isopropylcarbamate, 
(49a) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€ 
benZoyl)-L-lysyl-L-prolylmethyl]-N-isopropylcarbamate, 
(49b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N€ 
benZoyl)-L-lysyl-D-prolylmethyl]-N-isopropylcarbamate, 
(50a) p-Nitrophenyl N-[Methoxysuccinyl-L- alanyl-(Né 
carbobenZoxy)-L-ornithyl-L-prolylmethyl]-N 
isopropylcarbamate, 
(50b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N6 
carbobenZoxy)-L-ornithyl-D-prolylmethyl]-N 
isopropylcarbamate, 
(5 1a) p-Nitrophenyl N-[Methoxysuccinyl-L- alanyl-(Né 
benZoyl)-L-ornithyl-L-prolylmethyl]-N 
isopropylcarbamate, 
(51b) p-Nitrophenyl N-[Methoxysuccinyl-L-alanyl-(N6 
benZoyl)-L-ornithyl-D-prolylmethyl]-N 
isopropylcarbamate, 
(52) S-(1-phenyl-5-tetraZol) chloroformate, 
(53) S-(1-phenyl-5-tetraZoyl)-N-[(N-Boc-L-prolyl)methyl] 
N-isopropylthiocarbamate, 
(54) S-(1 -phenyl-5-tetraZoyl-N-prolymethyl)-N 
isopropylthiocarbamate hydrochloride, 
(PC5) S-(1-phenyl-5-tetraZoyl)-N-[methoxysuccinyl 
alanyl-(N€-CarbobenZoxy) lysyl prolyl methyl]-N 
isopropyl-thiocarbamate, or 
(PC6) S-(1-phenyl-5-tetraZoyl)-N-[methoxysuccinyl-(N 
carbobenZoyl)ornithylalanyl (prolylmethyl)-N 
isopropylthio carbamate. 
Also suitable, however, are other polymer-bound HLE 
inhibitory agents Which can be prepared by chemically 
binding knoWn HLE inhibitory agents to someWhat hydro 
philic and/or Water-soluble polymers as an artisan Would 
knoW, and is for example described in US. Pat. No. 5,162, 
307 to Digenis et al, described supra. 
In general, the polymers suitable for use in this invention 
are Water soluble polymers, and preferably, polymers having 
a ?exible backbone structure Which are not easily biode 
gradable and Which consequently have a prolonged biologi 
cal half life. Even more preferred are polymers Which are 
Water soluble and substantially non-biodegradable but 
Which also have a ?exible polymer backbone. A high ?ex 
ibility exhibited by the polymer is helpful in increasing the 
accessibility of the polymer bound inhibitory molecule to 
the enZyme. 
Suitable polymers for use in this invention are polymers 
containing amide bonds in the main chain. Particularly 
useful are derivatives of synthetic polyamino acids, 
examples of Which include random copolymers of 0t, [3 
hydroxy alkyl-D,L-asp artamide, e.g., poly 0t, [3-(N-(2 
hydroxyethyl)-D,L-aspartamide) in Which a fraction of 
2-hydroxyethyl side-chains is replaced by appended reactive 
moieties having HLE inhibitory activity. 
Other examples of suitable polymers include polysaccha 
ride derivatives, especially derivatives of dextran, cellulose, 
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carboxymethyl cellulose, alginic acid and hyaluronic acid, 
combinations thereof or combinations With other polymers. 
Yet another example of suitable polymers With oxygen 
atoms in the main polymer chain are polyether polymers, 
examples of Which include polyethyleneglycol 
(polyoxirane), divinylethermaleic acid copolymer (pyran 
copolymer, DIVEMA), and the like. Examples of polymers 
With a-CC-backbone suitable for use in this invention are 
copolymers prepared from mixtures of different types of 
monomers. One such group is a polymer formed by mixing 
one type of monomer Which has active appended moieties 
and another type of monomer lacking such moieties. Par 
ticularly suitable are copolymers derived from hydrophilic 
vinylic and/or acrylic type monomers. Examples include 
N-2-vinylpyrrolidone, 2hydroxZypropylmethacrylamide, 
2hydroxyethylmethacrylate and other hydrophilic esters and 
amides of acrylic and methacrylic acid Which are Well 
knoWn in the art. Suitable monomers containing appended 
reactive moieties for preparation of copolymers for use in 
this invention include, e.g., maleic acid anhydride and 
reactive esters of acrylic and methacrylic acid. Particularly 
suitable are, e.g., glycidyl acrylate, glycidyl methacrylate, 
p-nitrophenyl, N-hydroxysuccinimide, pentachlorophenyl 
or/and penta?uorophenyl esters of methacrylic and acrylic 
acids, Wherein the alkoxy moiety of the reactive ester can be 
either bound directly to the carbonyl of methacrylic or 
acrylic acid or it can be bound via a spacer or linker. 
Suitable spacers or linkers for use in these types of 
polymers are generally knoWn in the art. Examples of 
particularly suitable polymers include poly(N 
vinylpyrrolidone), co-poly-(N-vinylpyrrolidone-co-maleic 
acid anhydride), co-poly- (N-vinylpyrrolidone-co 
methacryloyl-N-hydroxysuccinimide, co-poly(N-(2 
hydroxypropyl)methacrylamide-co-methacryloyl 
p-nitrophenyl ester) and other copolymers formed by the 
monomers indicated above. 
The polymers utiliZed for practicing the present invention 
must be pharmaceutically-acceptable polymers. These are 
knoWn in the art as such. 
Where the HLE inhibitory agents are attached to the 
polymer by means of a linker or spacer the linkers or spacers 
must contain at least tWo reactive groups. One of the reactive 
groups must be capable of covalently bonding to the 
appended moiety present in at least some of the monomer 
units contained in the polymer. The other reactive group 
must be capable of covalently bonding to a reactive group 
present in the free HLE inhibitory agent molecule Which is 
not involved in the binding to the active site of the enZyme. 
Suitable linkers are knoWn in the art and need not be 
speci?cally described herein. One group of linkers Which 
has been found suitable for use With this invention is that 
encompassing ?exible backbone hydrocarbons containing at 
least tWo reactive groups. Suitable are reactive groups such 
as hydroxyl, sulfhydryl, amino, carboxyl, hydraZino and 
hydroZido, among others. HoWever, other groups may also 
be utiliZed. The length of the linker or spacer may vary as 
desired for particular applications. Typically, (C2—C2O) 
hydrocarbon linkers are utiliZed, preferably linear hydrocar 
bons. HoWever, other types of molecules may also be 
incorporated herein. 
Particularly suitable types of linker or spacer has been 
found to be those comprising (C2—C20) hydrocarbons having 
covalently bonded substituents to the ?rst and last carbon 
atoms such as hydroxylamines. Other examples suitable for 
use in this invention are 0t, -diamines, 0t, -diamino alcohols 
and 0t, -diamino acids. By means of example, polymers With 
multiple-bound HLE inhibitory agents provide an opportu 
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nity to incorporate several inhibitory moieties into a single 
unit, thereby increasing the ef?ciency of the transfer of the 
inhibitory agent to the active site of the enZyme. This, in 
turn, optimiZes the af?nity of the polymer-bound inhibitor 
toWards the enZyme When compared With the loW-molecular 
Weight HLE inhibitory agent itself. 
The HLE inhibitory agents are prepared as is taught by the 
art. By means of example, a group of derivatiZed oligopep 
tides having HLE inhibitory activity may be prepared as 
described in US. Pat. Nos. 4,643,991; 5,162,307; and 5,008, 
245 all to Digenis et al. 
The loading of the HLE inhibitory agents onto the poly 
mers either alone or by means of a linker or spacer is 
conducted by chemical reactions Which are knoWn in the art 
and need not be described here in detail. The degree of 
loading, i.e., density of the HLE inhibitory units along the 
polymeric chain can be varied in a Way such that it is most 
appropriate in accordance With the loading desired. This can 
be attained by varying the experimental conditions, e.g., the 
number of appended HLE active moieties on the polymeric 
chain, the number of spacer groups and/or the ratio of HLE 
inhibitory groups to the polymer in the reaction. Examples 
of these are shoWn in the examples of Us. Pat. No. 
5,162,307 to Digenis et al. HoWever, other means can also 
be utiliZed for adjusting the density of the inhibitory units 
along the polymeric chain as is knoWn in the art. 
In a preferred embodiment of the invention, the method is 
practiced subsequent to an ocular operation, and the corneal 
scarring or ?broblast proliferation is therefore post 
operative. In another particular embodiment, the method of 
the invention is applied to corneal scarring or ?broblast 
proliferation Which is associated With ocular conjunctivitis 
or other ocular infections or biological damage. 
In another embodiment of the invention the method is 
applied to corneal scarring or ?broblast proliferation asso 
ciated With corneal burning or other heat-associated damage 
of the eye. 
In still another embodiment, the method of the invention 
is applied to corneal scarring or ?broblast proliferation 
Which is associated With mechanical injury or chemical 
injury. 
The method of the invention may be practiced by apply 
ing the HLE inhibitory agent topically, intraocularly, by 
injection or through a contact lens. Preferred is topical 
application. 
Typically, the HLE inhibitory agent is applied as a com 
position comprising an about 0.001—99.9 Wt. % aqueous 
solution of the agent, preferably about 0.01—99 Wt. % 
solution of the agent, and more preferably about 0.1—90 Wt. 
% solution thereof. Most preferably, the inhibitory agent is 
applied in accordance With the present invention as a com 
position comprising an aqueous solution containing about 
1—10 Wt. % of the agent. Other amounts hoWever may also 
be utiliZed. The composition may also contain other ingre 
dients knoWn as useful in ocular treatments. These are 
additives Which are knoWn in the art. 
In still another embodiment of the invention the above 
method may be applied as a preventative method to a subject 
Who is susceptible to the ocular condition. 
The HLE inhibitory agent may be applied to the eye of a 
subject at varied intervals of time. Typically, the interval of 
time Will depend on the residence time of the inhibitory 
agent in the eye. Thus, polymer-bound agents are “longer 
acting” and need not be reapplied for longer periods of time 
than free agents as is knoWn in the art. Typically, polymer 
bound HLE inhibitory agents may be applied every about 24 
hours to seven days, and in some instances even longer 
periods of time. The free HLE inhibitory agents may be 
reapplied every about one hour to 24 hours. HoWever, other 
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intervals are utiliZed as suitable for speci?c HLE inhibitory 
agents and ocular conditions. Also part of this invention is 
a method of reducing neovasculariZation of corneal scar 
tissue or ?broblast proliferation comprising applying to an 
area of a subject’s eye afflicted With the condition a 
neovasculariZation-inhibitory amount of a human leukocyte 
elastase (HLE) inhibitory agent under conditions and for a 
period of time effective to attain the desired effect. 
Typically, the application is conducted for a feW days to 
up to a feW months, and sometimes for longer periods of 
time as needed to attain the desired result. 
As in the case of the prior method the HLE inhibitory 
agent may be selected from the group consisting of free and 
Water-soluble polymer-bound HLE inhibitory agents 
described above and/or knoWn in the art. 
The method described herein may also be practiced by 
applying the inhibitory agent to corneal scarring or ?broblast 
proliferation associated With post-operative conditions. 
Thus, the agent may be applied immediately after surgery, or 
as soon as ocular bleeding stops. 
In another embodiment the corneal scarring or ?broblast 
proliferation to Which the method is applied is associated 
With ocular conjunctivitis or other ocular infections or 
biological damage. In this case, the corneal scarring is 
produced by injury associated With microorganisms lodged 
in the ocular cavity and/or tissues. The ocular composition 
may in such cases additionally contain an antibiotic or other 
drug for the purpose of ?ghting the infection as Well. In 
another embodiment, the method the invention may be 
applied to corneal scarring or ?broblast proliferation Which 
is associated With corneal burning or heat-coagulation inju 
ries. 
In still another embodiment the method may be practiced 
on corneal scarring or ?broblast proliferation Which is 
associated With mechanical injury of the eye, e.g., mechani 
cal injury of the ocular cornea. 
In still another embodiment the corneal scarring or ?bro 
blast proliferation the method is applied to is associated With 
chemical injury. This typically occurs by exposure of the 
eye, and particularly the cornea, to chemical products Which 
have a detrimental effect on ocular tissues. 
In one embodiment of this method of the invention the 
HLE inhibitory agent may be applied topically, 
intraocularly, by injection or through a contact lens. Pre 
ferred is the topical application of an ocular composition, 
e.g., a solution of the agent. By means of example a 
composition comprising an aqueous solution of the com 
pound may be applied to the eye as an about 0.001—99.9 Wt. 
% solution thereof, preferably about 0.01—99 Wt. %, and 
more preferably about 0.1—90 Wt. %. A most preferred 
composition comprises a solution of the HLE inhibitory 
agent of about 1—10 Wt. % thereof. 
In still another embodiment, this method of the invention 
is a preventative method Wherein the HLE inhibitory agent 
is applied to a subject susceptible to the condition prior to its 
occurrence. 
Having noW generally described this invention, the same 
Will be better understood by reference to certain speci?c 
examples, Which are included herein for purposes of illus 
tration only and are not intended to be limiting of the 
invention or any embodiment thereof, unless so speci?ed. 
EXAMPLES 
Example 1: Chemicals and Solutions 
The folloWing tWo representative compounds, KY7-11A 
and KY-3-PC5, compounds A and B, respectively, Were 
tested for use in the methods of the invention. 
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Exemplary HLE Inhibitory Agents Utilized 
NH 
N02 
0 o 0 
NH 0 CH3 
NH N 
NH N 
o 
o 0 CH3 
and 
Z 
Ph 
cH3 H o 0 Y IL 
N N 5% \W \
N \H/ N/N 
o H o 0 
NH 
\ 
Compound 1 is a peptidyl carbamate elastase (HLE) 
inhibitor Which is chemically bound to a non-biodegradable 
Water soluble polymer With an average molecular Weight of 
about 1,000 to 5000,000 daltons. This compound is 
described in US. Pat. No. 5,162,307. Compound 2 is a 
peptidyl carbamate elastase (HLE) inhibitor and is repre 
sentative of a large series of peptidyl carbamate HLE 
inhibitors described in US. Pat. No. 5,008,245. 
Example 2: Solutions Tested 
(1) Solution A: Control 
This solution consists of normal saline (0.9% NaCl) and 
contains 1.4% W/V of polyvinyl alcohol. This solution Was 
used as a control. 
(2) Solution B: 
This solution contains the active elastase inhibitory agent 
(Compound 1 or Compound 2) at a concentration of 10 
pg/mL. The inhibitory agent Was dissolved in normal saline 
(0.9% NaCl) containing 1.4% W/v of polyvinyl alcohol. 
(3) Solution C: 
This solution contains the elastase inhibitory agent Com 
pound 2 at a concentration of 50 pg/mL. This inhibitory 
agent Was dissolved in normal saline (0.9% NaCl) contain 
ing 1.4% W/v of polyvinyl alcohol. 
All the above solutions Were freshly made immediately 
prior to conducting the tests. The samples Were then kept 
under refrigeration at 5° C. 
Example 3: Animal Experiments 
All surgery Was performed by a Board-certi?ed ophthal 
mologist (M.D.). Sedation and euthanasia Were performed 
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by a veterinarian (DVM) ophthalmologist (M.D.) under 
aseptic conditions. Histopathology Was conducted by an 
expert pathologist (MD) at the University of Miami, 
School of Medicine, Miami, Fla. and the Pathology Labo 
ratory at the Ophthalmology Department at the University of 
IoWa, IoWa City, IoWa. 
All samples Were coded and all the above mentioned 
operators had no knowledge of the key to the code (blind 
test). 
Example 4: General Animal Preparation 
26 rabbits Were tranquiliZed With acetylpromaZine 
maleate, 16 mg/kg intramuscularly. 2% lidocaine HCl eye 
drops Were instilled in each eye for corneal anesthesia. Once 
the corneas Were anesthetized, an eyelid speculum Was 
inserted and the lids Were then separated. 
The corneas of each eye Were thermally coagulated With 
the tip of a battery-powered ophthalmic cautery. A burn 
measuring 3 mm in diameter Was placed near the superior 
limbus of each eye. 
TWo drops of solution A, B or C Were instilled in 
designated treated eyes every 15 min for 6 hrs., then every 
2 hrs. for 12 hrs. FolloWing this, tWo eye drops of the same 
solutions Were instilled four times a day. Daily eye exami 
nation Was performed and photographs Were taken. 
TWo Weeks after treatment the rabbits Were sacri?ced by 
longer intracardiac injection of T-61 (50 pmg/kg). 
Subsequently, the rabbits, eyeballs Were enucleated, the 
globes placed in Bounri’s solution (10% formalin solution) 
and submitted for histopathology cell analysis. 
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Example 5: Histopathological Results 
The eyes Were ?xed With 10% formalin solution and 
labeled right (R) and left (L), as appropriate sectioned and 
stained With H & E (hematoxylin & eosin stains). Histo 
logical sections Were read by a pathologist Without knoWl 
edge of the previously undertaken experimental procedure 
(blind test). 
Table 2 beloW shoWs typical results obtained from a 
minimum of six (6) rabbits per treatment. 
TABLE 2 
Microscopic Description of Rabbit Eyes 
Treatment Results 
Untreated Solution A 
(normal saline & 1.4% 
W/v polyvinyl alcohol) 
Eyes (the untreated ones) showed an 
area, 5-6 mm in extent, and involving 
the entire thickness of the cornea, of 
vascular and ?broblastic 
proliferation With an intense 
in?ammatory in?ltrate consisting 
predominantly of eosinophils, With 
very feW plasma cells and lymphocytes. 
In that area the surface epithelium 
Was ulcerated. The deeper one half of 
the cornea showed almost a pure 
?broblastic proliferation With 
collagent deposition. In most of the 
cases an intense stromal 
vascularization With central scarring 
and the presence of numerous 
polymorphonuclear leukocytes, Were 
observed. 
The reaction is not quite as intense 
as in the untreated specimen. ToWard 
the periphery of the specimen, of 
corneal vascularization and migration 
?broblasts into the cornea, Was or 
observed. Centrally, there Was a Zone 
of super?cial scarring, just beneath 
the corneal epithelium. 
Super?cially, a Zone of proliferating 
?broblasts around the carotid 
collagen, Was also noticed. 
In contrast to the “untreated” eyes, 
the treated eyes (With Solution C) 
exhibited focal areas of subepithelial 
vascular proliferation of only 0.6 
1.0 mm in extent and involved only one 
third of the corneal thickness. This 
represents a protection against 
scarring, due to corneal burns of a 
tenfold magnitude. 
Treated With Solution 
B (10 ,ug/ml of 
Compounds 1 or 2) 
Treated With Solution 
C (50 ,ug/ml Comp. B) 
The above histopathologic results shoW that after appli 
cation of the solutions (Solution A, B or C), severe ?brosis 
and neovasculariZation Was still present in the control or 
untreated corneas While very little neovasculariZation or 
?brosis could be detected in the experimental corneas 
(especially those treated With solution C). Accordingly, 
ophthalmic solutions of Compound 1 or Compound 2, Which 
are representative of a larger group of HLE inhibitory 
agents, are proven effective in reducing ?brosis, neovascu 
lariZation and in?ammation in corneal Wound-healing. 
The invention noW being fully described, it Will be 
apparent to one of ordinary skill in the art that many changes 
and modi?cations can be made thereto Without departing 
from the spirit or scope of the invention as set forth herein. 
We claim: 
1. A method of reducing corneal scarring or ?broblast 
proliferation comprising administering to an area of a sub 
ject’s eye afflicted With the condition a corneal scar-reducing 
or ?broblast proliferation-reducing amount of a human 
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leukocyte elastase (HLE) inhibitory agent under conditions 
and for a period of time effective to attain a scar-reducing or 
?broblast proliferation-reducing effect; 
Wherein the HLE inhibitory agent is selected from the 
group consisting of 
(a) carbamates substituted by oligopeptides and described by 
the folloWing general formula (I): 
R1 
Wherein Z is selected from the group consisting of R“O-Suc 
Wherein 
R“ is loWer alkyl of 1 to 3 carbon atoms, and CF3CO—; 
X is oxygen or sulfur; R‘ is selected from the group 
consisting of straight or secondary branched-chain 
alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon 
atoms, alkynyl of 2 to 4 carbon atoms; and cycloalkyl 
of 3 to 6 carbon atoms and R is selected from the group 
consisting of substituted or unsubstituted phenyl 
Wherein the substituents are selected from the group 
consisting of nitro, ?uoro, benZyl, CH2CF2CF2CF3, 
1-loWer alkyl tetraZolyl-, 1-phenyltetraZolyl-, 2-thioxo 
3-thiaZolindyl, pyridyl, and benZothiaZolyl, provided 
that When R is p-nitrophenyl, R‘ is other than tertiary 
butyl, benZyl or cyclohexyl, and When X is sulfur, R is 
other than benZyl; 
(b) a polymer of the formula 
Wherein 
P is a polymer comprising at least one unit of the formula 
(AmBn), Wherein (AmBn) are substantially nonbiodegradable 
polymer units and has an average molecular Weight of about 
1,000 to 500,000 daltons, m and n may be the same or 
different and are about 5 to 3,000, and A and B may be the 
same or different and at least one of A and B is capable of 
covalently binding to one of L and R4; 
Wherein R4 is selected from the group consisting of: 
(i) a substituent C of the formula; 
(C) 
o 
Wherein 
X1 is oxygen or sulfur, 
R5 is selected from the group consisting of straight and 
secondary branch-chained (C1—C4) alkyl, (C2—C3) 
alkenyl, (C2—C4) alkynyl, (C3—C6) cycloalkyl, and 
benZyl, 
R6 is selected from the group consisting of substituted and 
unsubstituted phenyl, Wherein the substituents are 
selected from the group consisting of nitro, penta?uoro, 
benZyl, CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl, 
1-phenyltetraZolyl, 2-thioxo-3-thiaZolidinyl-, pyridyl 
and benZothiaZolyl, provided that When R6 is 
p-nitrophenyl, R5 is other than tert-butyl, benZyl or 
cyclohexyl, and When X1 is sulfur, R6 is other than 
benZyl; 
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a compound of the formula 
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(ii) a substituent D of the formula 
(IV) (D) 
wherein 
X2 is O or S, 
R8 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, 1-loWer 
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3- 15 
thiaZolidinyl, pyridyl and benZothiaZolyl; and Wherein 
R7 is selected from the group consisting of straight or X 15 1 or 2; 
Y is carbobenZoXy or benZoyl; and 
secondary branch chained (C1—C4) alkyl, (C2—C3) X3R15 in formulae (III) and (IV) is 
alkenyl, (C2—C4) alkynyl, (C3—C6) cycloalkyl, and 20 
benZyl, provided that When R8 is p-nitrophenyl, R7 is 
other than tertiary-butyl, benZyl or cycloheXyl, and 
When X2 is sulfur, R8 is other than benZyl; and 
25 (iii) a substituent E of the formula 
(E) 
and P6, P5, P4, P3, P2, P1 and P1‘ de?ne regions of formulae 
(III) and (IV). 
2. The method of claim 1, Wherein 30 
the corneal scarring or ?broblast proliferation is post 
operative. 
3. The method of claim 1, Wherein 
the corneal scarring or ?broblast proliferation is associ 
35 ated With ocular infection. 
4. The method of claim 1, Wherein Wherein 
the corneal scarring or ?broblast proliferation is associ 
ated With corneal burning. 
5. The method of claim 1, Wherein 
Z2 is —O—Suc-Ala-Ala; 
each said R4 being covalently bound to L or to one of A 40 the corneal scarring or ?broblast proliferation is associ 
ated With mechanical injury. 
6. The method of claim 1, Wherein 
and B, 
L is selected from the group consisting of a covalent bond 
and a linker group Which is covalently bound I0 R4 and the corneal scarring or ?broblast proliferation is associ 
one ofA and B; and 
q is about 1 to m+n; and 
ated With chemical injury. 
45 7. The method of claim 1, Wherein the inhibitory agent is 
applied topically. 
8. The method of claim 1, Wherein 
(c) a compound selected from the group consisting of the inhibitory agent is applied as an about 0.001 to 99.9% 
50 aqueous solution. 
9. The method of claim 1, Wherein a compound of the formula 
the corneal scarring or ?broblast proliferation is post 
operative. 
10. The method of claim 1, Wherein 
(111) 
55 the corneal scarring or ?broblast proliferation is associ 
ated With ocular infection. 
11. The method of claim 1, Wherein 
the corneal scarring or ?broblast proliferation is associ 
ated With corneal burning. 
6O 12. The method of claim 1, Wherein 
the corneal scarring or ?broblast proliferation is associ 
ated With mechanical injury. 
13. The method of claim 1, Wherein 
the corneal scarring or ?broblast proliferation is associ 
65 ated With chemical injury. 
14. A method of reducing neovasculariZation of corneal 
scar tissue comprising administering to an area of a subj ect’s and 
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eye a neovasculariZation-inhibitory amount of an HLE 
inhibitory agent under conditions and for a period of time 
effective sufficient to reduce neovasculariZation of corneal 
scar tissue Wherein the HLE inhibitor agent is selected from 
the group consisting of 
(a) carbamates substituted by oligopeptides and described by 
the following general formula (I): 
RI 
Wherein Z is selected from the group consisting of R“O-Suc 
Where R“ is loWer alkyl of 1 to 3 carbon atoms, and 
CF3CO—; X is oXygen or sulfur; R‘ is selected from the 
group consisting of straight or secondary branched-chain 
alkyl of 1 to 4 carbon atoms, alkenyl of 1 to 4 carbon atoms, 
alkynyl of 2 to 4 carbon atoms; and cycloalkyl of 3 to 6 
carbon atoms, and R is selected from the group consisting of 
substituted or unsubstituted phenyl Wherein the substituents 
are selected from the group consisting of nitro, ?uoro, 
benZyl, CH2CF2CF2CF3, 1-loWer alkyl tetraZolyl-, 
1-phenyltetraZolyl-, 2-thioXo-3-thiaZolindyl, pyridyl, and 
benZothiaZolyl, provided that When R is paranitrophenyl, R‘ 
is other than tertiary-butyl, benZyl or cycloheXyl, and When 
X is sulfur, R is other than benZyl; 
(b) a polymer of the formula 
Wherein 
P is a polymer comprising at least one unit of the formula 
(AmBn), Wherein (AmBn) are substantially nonbiode 
gradable polymer units and has an average molecular 
Weight of about 1,000 to 500,000 daltons, m and n may 
be the same or different and are about 5 to 3,000, and 
A and B may be the same or different and at least one 
of A and B is capable of covalently binding to one of 
L and R4; 
Wherein R4 is selected from the group consisting of 
(i) a substituent C of the formula: 
(C) 
o 
Wherein 
X1 is oxygen or sulfur; 
R5 is selected from the group consisting of straight and 
secondary branch-chained (C1—C4) alkyl, (C2—C3) 
alkenyl, (C2—C4) alkynyl; and (C3—C6) cycloalkyl, and 
benZyl, and 
R6 is selected from the group consisting of substituted and 
unsubstituted phenyl, Wherein the substituents are 
selected from the group consisting of nitro, penta?uoro, 
benZyl, CF2CF2CF2CF3, 1-loWer alkyl tetraZolyl, 
1-phenyltetraZolyl, 2-thioXo-3-thiaZolidinyl-, pyridyl 
and benZothiaZolyl, provided that When R6 is 
p-nitrophenyl, R5 is other than tert-butyl, benZyl or 
cycloheXyl, and When X1 is sulfur, R6 is other than 
benZyl; 
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(ii) a substituent D of the formula; 
(D) 
o 
Wherein 
X2 is O or S, 
R8 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, 1-loWer 
alkyltetraZolyl, 1-phenyltetraZolyl, benZyl, 2-thioXo-3 
thiaZolidinyl, pyridyl and benZothiaZolyl, and 
R7 is selected from the group consisting of straight or 
secondary branch chained (C1—C4) alkyl, (C2—C3) 
alkenyl, (C2—C4) alkynyl; and (C3—C6) cycloalkyl, and 
benZyl, provided that When R8 is p-nitrophenyl, R7 is 
other than tertiary-butyl, benZyl or cycloheXyl, and 
When X2 is sulfur, R8 is other than benZyl; and 
(iii) a substituent E of the formula 
(E) 
o 
Wherein 
Z2 is —O—Suc-Ala-Ala; 
each said R4 being covalently bound to L or to one of A 
and B, 
L is selected from the group consisting of a covalent bond 
and a linker group Which is covalently bound to R4 and 
one ofA and B; and 
q is about 1 to m+n; and 
(c) a compound selected from the group consisting of a 
compound of the formula 
(111) 
0 CH3 H Y rlv N X3R15 
| 
| 
| 
| 
| 
| 
Me 
| 
| 
| T 
O H O 
NH 
/ 
Y 
P3 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
P6 I 
I 
and 



